Amgen's Investigational Targeted Treatment Bemarituzumab Granted Breakthrough Therapy Designation

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/2/2026

1. PANW
2. GTLB
3. MDB
4. DELL
5. VRTS
6. GOOGL
7. SPY
8. HPE
9. SNOW
10. USO

Go back to Amgen's Investigational Targeted Treatment Bemarituzumab Granted Breakthrough Therapy Designation
Amgen Inc (NASDAQ: AMGN) Delayed: 442.84 +4.72 (1.08%)
Previous Close $438.12    52 Week High $176.85 
Open $440.65    52 Week Low $133.64 
Day High $445.57    P/E 66.69 
Day Low $435.00    EPS $6.64 
Volume 2,286,285